Prognostic factors and survival of patients undergoing surgical intervention for breast cancer bone metastases

被引:6
|
作者
Hankins, Margaret L. [1 ]
Smith, Clair N. [1 ]
Hersh, Beverly [2 ]
Heim, Tanya [1 ]
Belayneh, Rebekah [1 ]
Dooley, Sean [1 ]
Lee, Adrian, V [3 ]
Oesterreich, Steffi [3 ]
Lucas, Peter C. [4 ]
Puhalla, Shannon L. [2 ]
Weiss, Kurt R. [1 ]
Watters, Rebecca J. [1 ]
机构
[1] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Pittsburgh, PA 15219 USA
[2] Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA 15219 USA
[3] UPMC Hillman Canc Ctr, Womens Canc Res Ctr, Pittsburgh, PA USA
[4] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA 15219 USA
关键词
Breast cancer; Bone metastasis; Prognostic factor; Cancer management; CLINICAL-COURSE; CHEMOTHERAPY; MUTATIONS; WOMEN; CARCINOMA; EFFICACY; DISEASE; BINDING;
D O I
10.1016/j.jbo.2021.100363
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Bone is the most common distant site of breast cancer metastasis. Skeletal lesions can cause significant morbidity due to pain, pathologic fracture, and electrolyte abnormalities. Current treatment for patients with bone metastases (BoM) from breast cancer is highly personalized and often involves a multidisciplinary approach with chemotherapy, hormone therapy, bone-targeted antiresorptive agents, radiation therapy, and surgery. We have retrospectively collected clinical data from a series of patients with bone metastases to evaluate the clinical characteristics, prognostic factors, and survival patterns of patients with breast cancer BoM receiving standard multimodal therapy. Methods: A consecutive series of 167 patients with breast cancer BoM treated at a single institution between August 2013 and March 2020 were identified. Clinical information was obtained from the medical record and survival analyses were performed to evaluate patient outcomes and identify prognostic factors. Results: Thirty-seven patients (22%) presented with de novo BoM - bone metastases at the time of breast cancer diagnosis - and were 2.6 times more likely to die within the study period than those with asynchronous BoM (HR = 2.62, p = <0.0001). Patients who received bone-targeted medical therapy were 61% less likely to die after BoM diagnosis than those who did not (HR = 0.39, p = 0.001). Operative stabilization of BoM was more frequently employed in patients with lytic (p = 0.02) or mixed (p = 0.02) tumors than it was for those with blastic lesions. Patients treated with surgery had a lower overall bone metastasis survival than those treated without (p < 0.03). Discussion: These findings reflect the current patterns in metastatic breast cancer treatment and associated outcomes. In a series of 167 consecutive patients, we demonstrate the natural history of breast cancer with BoM being treated with modern multimodal therapy. Understanding these treatment patterns and prognostic factors enhances the provider's ability to counsel patients and direct appropriate treatments. (c) 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Prognostic Factors for Bone Survival and Functional Outcomes in Patients With Breast Cancer Spine Metastases
    Qiao, Rui-Qi
    Zhang, Hao-Ran
    Ma, Rong-Xing
    Li, Rui-Feng
    Hu, Yong-Cheng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [2] Prognostic factors for survival in patients with breast cancer and liver metastases
    Lumachi, F.
    Santeufemia, D. A.
    Chiara, G. B.
    Basso, S. M. M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S192 - S192
  • [3] Prognostic factors for survival in patients with bone metastases
    Samper Ots, P. M.
    Hernandez Miguel, M.
    Amaya Escobar, E.
    De las Penas Cabrera, M. D.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S745 - S745
  • [4] Resection of liver metastases in patients with breast cancer: Survival and prognostic factors
    van Walsum, G. A. M.
    de Ridder, J. A. M.
    Verhoef, C.
    Bosscha, K.
    van Gulik, T. M.
    Hesselink, E. J.
    Ruers, T. J. M.
    van den Tol, M. P.
    Nagtegaal, I. D.
    Brouwers, M.
    van Hillegersberg, R.
    Porte, R. J.
    Rijken, A. M.
    Strobbe, L. J. A.
    de Wilt, J. H. W.
    EJSO, 2012, 38 (10): : 910 - 917
  • [5] PROGNOSTIC FACTORS FOR BONE METASTASES IN BREAST-CANCER
    ULLOA, MAD
    MERCHAN, ECR
    INTERNATIONAL ORTHOPAEDICS, 1993, 17 (01) : 60 - 63
  • [6] Prognostic factors for survival of women with unstable spinal bone metastases from breast cancer
    Foerster, Robert
    Bruckner, Thomas
    Bostel, Tilman
    Schlampp, Ingmar
    Debus, Juergen
    Rief, Harald
    RADIATION ONCOLOGY, 2015, 10
  • [7] Prognostic factors for survival of women with unstable spinal bone metastases from breast cancer
    Robert Foerster
    Thomas Bruckner
    Tilman Bostel
    Ingmar Schlampp
    Juergen Debus
    Harald Rief
    Radiation Oncology, 10
  • [8] Survival in breast cancer patients with bone metastases
    El-Habbash, M.
    Alwindi, A.
    BREAST, 2007, 16 : S58 - S58
  • [9] Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases
    Parkes, Amanda
    Warneke, Carla L.
    Clifton, Katherine
    Al-Awadhi, Aydah
    Oke, Oluchi
    Pestana, Roberto Carmagnani
    Alhalabi, Omar
    Litton, Jennifer K.
    Hortobagyi, Gabriel N.
    ONCOLOGIST, 2018, 23 (11): : 1282 - 1288
  • [10] SURVIVAL AND PROGNOSTIC FACTORS IN CEREBRAL METASTASES OF BREAST-CANCER
    TRILLET, V
    CHAUVIN, F
    POMMATAU, E
    CLAVEL, M
    PRESSE MEDICALE, 1986, 15 (16): : 741 - 744